BACKGROUND: Mixed depression (MxD) is narrowly defined in the DSM-IV and somewhat broader in the DSM-5, although both exclude psychomotor agitation as a diagnostic criterion. This article proposes a clinical description for defining MxD, which emphasizes psychomotor excitation. METHODS: Two hundred and nineteen consecutive outpatients were diagnosed with an MxD episode using criteria proposed by Koukopoulos et al. [Acta Psychiatr Scand 2007;115(suppl 433):50-57]; we here report their clinical features and antidepressant-related effects. RESULTS: The most frequent MxD symptoms were: psychic agitation or inner tension (97%), absence of retardation (82%), dramatic description of suffering or weeping spells (53%), talkativeness (49%), and racing or crowded thoughts (48%). MxD was associated with antidepressants in 50.7% of patients, with similar frequency for tricyclic antidepressants (45%) versus selective serotonin reuptake inhibitors (38.5%). Positive predictors of antidepressant-associated MxD were bipolar disorder type II diagnosis, higher index depression severity, and higher age at index episode. Antipsychotic or no treatment was protective against antidepressant-associated MxD. CONCLUSIONS: MxD, defined as depression with excitatory symptoms, can be clinically identified, is common, occurs in both unipolar depression and bipolar disorder, and is frequently associated with antidepressant use. If replicated, this view of MxD could be considered a valid alternative to the DSM-5 criteria for depression with mixed features.
BACKGROUND: Mixed depression (MxD) is narrowly defined in the DSM-IV and somewhat broader in the DSM-5, although both exclude psychomotor agitation as a diagnostic criterion. This article proposes a clinical description for defining MxD, which emphasizes psychomotor excitation. METHODS: Two hundred and nineteen consecutive outpatients were diagnosed with an MxD episode using criteria proposed by Koukopoulos et al. [Acta Psychiatr Scand 2007;115(suppl 433):50-57]; we here report their clinical features and antidepressant-related effects. RESULTS: The most frequent MxD symptoms were: psychic agitation or inner tension (97%), absence of retardation (82%), dramatic description of suffering or weeping spells (53%), talkativeness (49%), and racing or crowded thoughts (48%). MxD was associated with antidepressants in 50.7% of patients, with similar frequency for tricyclic antidepressants (45%) versus selective serotonin reuptake inhibitors (38.5%). Positive predictors of antidepressant-associated MxD were bipolar disorder type II diagnosis, higher index depression severity, and higher age at index episode. Antipsychotic or no treatment was protective against antidepressant-associated MxD. CONCLUSIONS: MxD, defined as depression with excitatory symptoms, can be clinically identified, is common, occurs in both unipolar depression and bipolar disorder, and is frequently associated with antidepressant use. If replicated, this view of MxD could be considered a valid alternative to the DSM-5 criteria for depression with mixed features.
Authors: S Nassir Ghaemi; Jules Angst; Paul A Vohringer; Eric A Youngstrom; James Phelps; Philip B Mitchell; Roger S McIntyre; Michael Bauer; Eduard Vieta; Samuel Gershon Journal: Int J Bipolar Disord Date: 2022-10-13
Authors: Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno Journal: Neuropsychopharmacology Date: 2021-06-30 Impact factor: 7.853
Authors: Andrea Fagiolini; Anna Coluccia; Giuseppe Maina; Rocco N Forgione; Arianna Goracci; Alessandro Cuomo; Allan H Young Journal: CNS Drugs Date: 2015-09 Impact factor: 5.749
Authors: Chi Ming Leung; Chi Lap Yim; Connie T Y Yan; Cheuk Chi Chan; Yu-Tao Xiang; Arthur D P Mak; Marcella Lei-Yee Fok; Gabor S Ungvari Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240
Authors: Gabriele Sani; Alessio Simonetti; Daniela Reginaldi; Alexia E Koukopoulos; Antonio Del Casale; Giovanni Manfredi; Georgios D Kotzalidis; Paolo Girardi Journal: Curr Neuropharmacol Date: 2017-04 Impact factor: 7.363